New research identifies diabetes as an independent predictor of major adverse cardiovascular events in patients with both ...

Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong second-quarter sales of key ...

Novartis AG announced disappointing sales for a key psoriasis drug and the looming retirement of its respected finance chief, which overshadowed a modest outlook raise.

On behalf of our sponsors at Arcutis Biotherapeutics, we're learning more about Plaque Psoriasis, the chronic, inflammatory skin disease that affects many people and a new topical treatment that may ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Disability Pride Month is needed more than ever. It’s an important reminder of how far we’ve come in terms of representation, ...

Quarterly pharmaceutical sales surpassed $15 billion for the first time as strong performance from J&J's cancer medicines ...

NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

BERLIN ― Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong revenue growth from products such as breast cancer drug Kisqali during the second quarter.

Johnson & Johnson reported second-quarter results on July 16. Sales of pharmaceuticals have been muted due to a loss of ...

Kids’ interest in skincare is often portrayed as fun or harmless, DeFino told me. But beauty “is a multibillion-dollar ...